Cantor Fitzgerald reiterates an Overweight rating on Avita Medical (RCEL) following the company receiving FDA premarket approval for RECELL GO Mini, its miniaturized device designed to treat smaller wounds that aren’t addressed by RECELL GO. Importantly, the firm expects that approval for Mini will allow the company to target smaller wounds within the company’s full thickness skin defect indication. Cantor notes Avita plans to roll out Mini across trauma and burn centers that treat smaller wounds during Q1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCEL:
